Mesoblast (MSB.AU)

Mesoblast share price today, ATLAS forecast and fair value

Healthcare · Biotechnology · Australian Securities Exchange · Australia

A$1.86▲ +3.92%

Prices as of Oct 27, 2026 · AUD

ATLAS fair value

ATLAS has no fair value for this stock today.

Chance of rising in 1 month

47%

that it ends higher than today in 21 sessions

0%coin flip 50%100%

This is just the summary. See everything on Mesoblast in ATLAS

ATLAS's own quantitative analysis, all in one place.

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.

See everything included

Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

On Mesoblast

Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
Officers and shareholdersWho runs the company and which funds hold its shares.
Customer and supplier mapWho it does business with, from its own filings.
Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
NewsThe latest on the company, in one place.

And for you

ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
AlertsWe let you know when something changes in your stocks.
Crisis simulatorHow your portfolio would do in a crash like 2008.
Practice risk-free$10,000 in virtual money to invest at real prices.
Global screenerSearch US stocks and stocks from 47 countries with filters.

Get started →

Plans from €3.99 a month.

ATLAS's model gives Mesoblast a 47% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.

In half of the simulated outcomes the price ends between A$1.65 and A$2.04; in 9 out of 10, between A$1.37 and A$2.46. Estimated annual volatility is 55%.

Price, last 12 months (weekly close)

Key numbers

Market cap: A$2.5B
Market cap (USD): $1.7B
52-week high: A$3.31
52-week low: A$1.74
Revenue (12 months): $120M
Gross margin: 80.0%
Operating margin: -33.3%
Net margin: -47.8%
Beta: 0.86

What this means

ATLAS does not publish a fair value for MSB.AU right now, but it does show its odds of rising: close to a coin flip.

Over the last 52 weeks MSB.AU has traded between A$1.74 and A$3.31. Today it is 44.0% below that high and 7% above its low.

Its beta is 0.86: it moves roughly in line with the market.

About the company

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

Want to see everything about Mesoblast?

Get started →

Plans from €3.99 a month.

Comparable companies

Other companies in the same line of business:

Frequently asked questions

What does Mesoblast do?

What is the chance MSB.AU goes up next month?

47%: close to a coin flip. In half of the simulated outcomes, MSB.AU ends the month between A$1.65 and A$2.04.

How big is Mesoblast and what is its P/E ratio?

Mesoblast's market capitalization is A$2.5B. We do not show a P/E because it has no positive earnings to base one on.

How volatile is MSB.AU?

ATLAS estimates annual volatility at 55%. In a typical month, half of the outcomes end between A$1.65 and A$2.04.

Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer